Dubois, Bruno
López-Arrieta, Jesús
Lipschitz, Stanley
Doskas, Triantafyllos
Spiru, Luiza
Moroz, Svitlana
Venger, Olena
Vermersch, Patrick
Moussy, Alain
Mansfield, Colin D.
Hermine, Olivier
Tsolaki, Magda
,
Article History
Received: 1 August 2022
Accepted: 15 January 2023
First Online: 28 February 2023
Change Date: 22 April 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13195-023-01230-9
Declarations
:
: Study AB09004 was conducted according to the Declaration of Helsinki, Good Clinical Practice (GCP) guidelines, and national regulations. An independent data monitoring committee periodically reviewed blinded patient safety and efficacy data. The trial protocol was approved by the appropriate Independent Ethics Committee/Institutional Review Board of all participating sites (including the ethics committee of General Hospital of Thessaloniki ‘George Papanikolaou’) and all subjects provided informed consent.
: Not applicable
: Masitinib is under clinical development by the study funder, AB Science. AM, OH, and CDM are employees and shareholders of AB Science. BD reports consultant fees from AB Science and Biogen and an institutional grant from Roche and Foundation Merck-Avenir. PV reports honoraria and consulting fees from Biogen, Sanofi-Genzyme, Novartis, Teva, Merck, Roche, Celgene, Imcyse, and AB Science; and research grants from Sanofi-Genzyme, Roche, and Merck. All remaining authors have no competing interests.